Portage Biotech Inc. announced the presentations of updates from its ongoing IMPORT-201 Phase 1/2 trial of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) engager for patients with NSCLC and advanced melanoma, and its ADPORT-601 adaptive Phase 1a/1b trial for PORT-6 (A2A inhibitor) and PORT-7 (A2B inhibitor) in multiple solid tumors at SITC. The patient data from IMPORT-201, a multi-arm Phase 1/2 trial evaluating PORT-2 in multiple settings, included front-line and refractory NSCLC, and refractory melanoma, as a monotherapy and in combination with Merck's anti-PD-1 therapy, KEYTRUDA®? (pembrolizumab).

SITC presentations are available now to registrants through the conference platform. Both posters will be added to the "Presentations & Publications" section of Portage's website following the conference. words such as " may, "will," "will," "should," "expect," "anticipate," "intend," "believe," "predict," "pot potential" or " continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words.